Heterogeneity of Aβ peptides, especially N-terminal truncated isoforms, were reported in AD patients as early as 1985 [3], and the identification of potential candidate enzymes being involved in the generation of such species from either APP or “full-length” Aβ [21,22] fueled current research interest. This evidence concerns the gene APP and Alzheimer disease.